Yumi Hironaka
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Journal: Leukemia
Published: February 09, 2019
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
Journal: Leukemia
Published: January 27, 2018
The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
Journal: European journal of haematology
Published: January 23, 2018
The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria.
Journal: American journal of hematology
Published: March 27, 2017
Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells.
Journal: The Journal of biological chemistry
Published: June 29, 2016
Identification of AIM2 as a downstream target of JAK2V617F.
Journal: Experimental hematology & oncology
Published: November 26, 2015
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.
Journal: Haematologica
Published: November 16, 2014
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Journal: International journal of hematology
Published: October 14, 2014
Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation.
Journal: PloS one
Published: September 06, 2014
JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.
Journal: International journal of hematology
Published: January 18, 2014
Last Updated: 09/26/2026